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ABSTRACT

HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes:
An Exploratory Association Study
by
Derek Edward Murrell
As HIV is now primarily a chronic condition, treatment is given life-long with changes as
necessitated by alterations in tolerability and efficacy. Thus, personalized medicine may be
useful in the prevention of unnecessary drug exposure and avoidable side effects. Three of the
four currently available HIV integrase strand transfer inhibitors (INSTIs), raltegravir,
elvitegravir, and dolutegravir, are widely utilized antiretrovirals in the USA and exhibit
variations in outcomes among subjects. To interrogate differences among subjects receiving
these drugs, we investigated the association of several single nucleotide polymorphisms (SNPs)
with drug exposure, clinical outcomes, and subject-reported adverse events. HIV+ adults (≥18
years old) receiving an INSTI regimen were recruited (n=88). Subject genotypes were evaluated
using an iPLEX PGx Panel. Genetic variations within our population, underwent multiple
regression with covariates [age, sex, BMI, regimen duration, and baseline variables (as required)
along with specific regimen in the comprehensive group] to detect significant (p<0.05)
associations with concentration and selected clinical data. Additionally, multiple logistic
regression, with the previous covariates, tested for association with binary traits including central
nervous system-related (abnormal dream, anxiety, fatigue, headache, and insomnia) and
gastrointestinal-related (diarrhea and nausea) adverse events. With a median age of 52.5 years
(IQR 45.7-57.2) being predominately Caucasian (88.6%) and male (86.4%), we found an
association (p=0.028) between abnormal dream occurrence and specific INSTI regimen with the
raltegravir grouping presenting a higher frequency. This exploratory study also discovered
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several SNP-outcome associations when using INSTIs. Although these SNPs were found to have
a role in predicting segments of adverse effect profiles, the clinical significance of these findings
remains to be determined. Larger studies will be needed to confirm these exploratory findings
with functional studies to understand pathogeneses. In conclusion, the associations found in this
study strengthen the need for further assessment, within the HIV+ population, of factors
contributing to unfavorable subject outcomes.
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CHAPTER 1
INTRODUCTION
After nearly four decades, human immunodeficiency virus (HIV) remains a high priority
in biomedical research with thousands of new infections occurring each day adding to the
upward of 36 million HIV positive individuals the world over ("HIV Data and Statistics," 2017).
Current drug treatments are highly effective in reducing plasma HIV viral load; however, several
factors may interact to alter the efficacy and tolerability of antiretrovirals (Gandhi et al., 2012;
Hewitt, 2002). Because HIV positive individuals are living relatively longer and healthier lives
due to improved treatment, the frequency and severity of side effects may increase with agerelated physiological changes and the increased probability of comorbidities (Dumond et al.,
2013). In addition, variations in the genetic make-up of an individual may also alter the behavior
of some drugs, resulting in differences in efficacy and toxicity (Wyatt, Pettit, & Harirforoosh,
2012). Compounded with the current absence of a cure, treatment regimens must be continued
lifelong. Thus, the availability of safe and continually effective treatment options is an increasing
concern to the HIV health care provider.
HIV: Overview
Transmission
HIV is typically contracted sexually, parenterally, or vertically (Shaw & Hunter, 2012).
Sexual contact involving the exchange of bodily fluids, such as semen or vaginal secretions,
possesses an increased probability of infection. Parenteral transmission, occurring through the
sharing of virally contaminated needles, is common among those who abuse intravenous drugs.
Vertical transmission occurs when the virus travels from mother to child through contact with
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maternal blood at birth, via breast feeding, or in utero. Other transmission avenues that are
possible, but less probable include accidental needle sticks, mucocutaneous exposure, or
contaminated blood/tissue transplants (DiPiro, 2011; Longo, 2012).
Replication
As a single-stranded RNA virus (two copies per retrovirus), HIV must enter a host cell to
replicate (Metifiot, Marchand, & Pommier, 2013). Infection occurs when HIV interacts with
CD4 receptors present on a host cell, primarily CD4+ T-cells, then fuses with the cell. The viral
coat is removed inside the cell revealing the viral RNA, which is reverse transcribed by a viral
enzyme, reverse transcriptase (RT), to complementary DNA (cDNA). Viral double-stranded
DNA (dsDNA), created from cDNA via host polymerases, is processed then translocated into the
cellular nucleus prior to integration into the host genome via HIV integrase (IN). This integration
creates a provirus which evades host immune responses through latency (Lampiris, 2012);
however, upon activation, the viral genome is expressed, leading to protein translation and
processing by viral proteases. Viral RNA, enzymes, and coat are then organized into mature
viruses, which bud from the host cell (Metifiot et al., 2013). Disease progression and
antiretroviral therapy efficacy may be determined using HIV RNA concentration in plasma and
CD4+ cell count as biomarkers (DeJesus et al., 2012; Sax et al., 2012; Zolopa et al., 2013).
Antiretroviral Therapy
Currently, there is no effective vaccine against or method of cure for HIV infection;
however, numerous antiretroviral medicines have been devised to combat the progression of HIV
infection into acquired immune deficiency syndrome (AIDS). Because no drug has proven to be
exceedingly effective individually and the HIV genome is capable of rapidly developing drug
resistance, the use of multiple drug classes each addressing a different aspect of HIV infection
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and replication is preferred. Thus highly active antiretroviral therapy (HAART), consisting of
one or more members of the following drug classes: protease inhibitor (PI), nucleoside and
nucleos(t)ide reverse transcriptase inhibitor (NRTI) or non-nucleoside reverse transcriptase
inhibitor (NNRTI), entry inhibitor, and/or integrase strand-transfer inhibitor (INSTI), has
become routine in the treatment of HIV (Metifiot, Marchand, Maddali, & Pommier, 2010; Olin,
Spooner, & Klibanov, 2012; Pavlos & Phillips, 2012; Zanger & Klein, 2013). Strict compliance
with medication regimens is required to avoid viral mutations which can render individual or
even classes of antiretrovirals ineffective. This study focused on three of the four currently
available INSTIs which were and remain frontline regimens (Tsiang et al., 2016). Bictegravir
was not included due to the lack of usage and clinical experience at the commencement of this
observational study.
Integrase Strand Transfer Inhibitors (INSTIs)
Mechanism of Action
Following reverse transcription of viral RNA by reverse transcriptase and synthesis of
dsDNA by cellular enzymes, viral IN recognizes the newly synthesized dsDNA and performs a
function known as 3’-processing (Dayam et al., 2008). Two bases, G and T, are removed from
both 3’ ends of the viral dsDNA then the pre-integration complex (PIC), consisting of processed
dsDNA, IN, and other necessary cofactors, moves to the nucleus. The dsDNA is initially
integrated into the host DNA through IN then completed via host DNA repair enzymes (Liao,
Marchand, Burke, Pommier, & Nicklaus, 2010).
IN consists of three subunits, an N-terminal domain, a catalytic domain, and a C-terminal
domain. The DNA binding function of the catalytic domain is targeted by INSTIs (Lampiris,
2012). Mg2+ ions are believed to be essential for the catalytic capabilities of IN as well as the
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formation of the PIC through dsDNA binding (Liao et al., 2010). INSTIs chelate the Mg2+ ions at
the active catalytic site of IN, preventing 3’-processing and dsDNA covalent binding (Pommier
& Marchand, 2012). Without the interaction between IN and dsDNA, viral DNA is unable to
integrate into the host genome and replication is not possible (Correll & Klibanov, 2008).
Raltegravir
Merck introduced raltegravir, formerly MK-0518, as the first FDA-approved INSTI in
October 2007 under the brand name of Isentress for adults then (December 2011) approved for
use in pediatric subjects (Hajimahdi & Zarghi, 2016; Traynor, 2007). Discovered while
searching for a HCV polymerase inhibitor, raltegravir is a derivative of dihydroxypyrimidine
carboxamide (Hajimahdi & Zarghi, 2016).
Although primarily administered twice daily as a film-coated 400 mg tablet, single 800 or
1200 mg doses have also been examined (Cahn et al., 2017; Eron et al., 2011). The 1200 mg
dose was recently approved by the FDA ("Isentress Prescribing Information," 2017).
Administration is not dependent upon the presence of food and pharmacokinetic boosting is not
necessary. In the fasted state, the time to reach maximum plasma concentration, or the Cmax,
(Tmax) is reached in 3 hours with a half-life of nearly 9 hours (Brainard, Wenning, Stone,
Wagner, & Iwamoto, 2011); however, raltegravir pharmacokinetics have been shown to be
variable within and between subjects (Rizk et al., 2012). Protein binding appears to be
approximately 83% with 51% of the drug being excreted unchanged in feces ("Isentress
Prescribing Information," 2017). Raltegravir undergoes glucuronidation via uridine diphosphate
glucuronosyltransferase (UGT) 1A1 (UGT1A1). Raltegravir is dosed with various antiretroviral
backbone regimens, such as tenofovir disoproxil fumarate/emtricitabine or tenofovir
alafenamide/emtricitabine.
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Several clinical studies have shown the utility of raltegravir. The double-blind
STARTMRK trial has demonstrated raltegravir efficacy (over five years) and superiority over
efavirenz/emtricitabine/tenofovir disoproxil fumarate (Lennox et al., 2009; Rockstroh et al.,
2011). The proportion of virally suppressed individuals with HIV RNA < 50 copies/ml at week
240 was 71% vs. 61% for raltegravir and efavirenz regimens, respectively. Although the
QDMRK study, in which groups received the tenofovir disoproxil fumarate/emtricitabine
background, showed that raltegravir (800 mg; once-daily) did not reach non-inferiority compared
to raltegravir (400; twice-daily) at 48 weeks, over 83% of the once-daily group achieved viral
suppression (Eron et al., 2011). Several reviews have provided further detail on each of the
studies concerning INSTIs (Raffi & Wainberg, 2012).
Elvitegravir
Elvitegravir, formally known as JTK-303 and GS-9137, is a hydroxyquinolone
(quinolone-3-car1boxylic acid derivative) which interferes with HIV viral integration (Correll &
Klibanov, 2008; Hajimahdi & Zarghi, 2016). Although discovered by Japan Tobacco, Gilead
Sciences currently produces two treatment options, Stribild and its younger sibling Genvoya,
which were approved for use in the United States by the FDA in August 2012 and November
2015, respectively ("Genvoya Prescribing Information," 2017). Both combination regimens
contain elvitegravir, cobicistat, and emtricitabine; while differing in the tenofovir prodrug (D. E.
Murrell, Harirforoosh, S, 2016; Sax et al., 2015). Elvitegravir has also been approved for
independent administration as Vitekta by the FDA and European Commission.
Elvitegravir is administered orally in tablet form with the presence of food playing a
significant role in bioavailability (Lampiris, 2012; Olin et al., 2012). When co-formulated in
Stribild, elvitegravir peak drug concentrations are achieved within 4 hours post dose and
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absorption is elevated when administered with food (light meal, increased 34% vs fasting; high
fat meal, increased 87% vs. fasting). Plasma protein binding is high for elvitegravir (98-99%)
and nearly 95% of the drug is excreted in feces (Ramanathan, Mathias, German, & Kearney,
2011).
Phase I metabolism of elvitegravir is performed by cytochrome P450 (CYP) 3A4
(CYP3A4); the drug can also undergo glucuronidation by UGT1A1/3 (Adams, Greener, &
Kashuba, 2012; Olin et al., 2012; Ramanathan, Kakuda, Mack, West, & Kearney, 2008). As an
inducer of CYP3A4 and CYP2C9, which diminishes the half-life of substrates metabolized by
these enzymes, elvitegravir has a relatively short half-life of 3 hrs (Adams et al., 2012). Rather
than increasing dosage to achieve appropriate systemic exposure, elvitegravir is administered
with a pharmaco-enhancer which decreases drug metabolism (Olin et al., 2012).
Originally paired with ritonavir, elvitegravir is now partnered with a more precise
inhibitor, cobicistat. Co-formulation with cobicistat, which triples the half-life of elvitegravir to 9
hrs, is beneficial in helping to prevent the development of drug resistance (Adams et al., 2012).
Also as elvitegravir is not altered by most NRTIs, co-formulation with emtricitabine and
tenofovir disoproxil fumarate is possible (Correll & Klibanov, 2008).
Elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine has been documented to be
non-inferior to efavirenz/tenofovir disoproxil fumarate/emtricitabine and to atazanavir (a
PI)/ritonavir+/tenofovir disoproxil fumarate/emtricitabine as evaluated by the proportion of
formerly drug-naïve patients demonstrating viral load suppression to below 50 copies RNA/ml
after 48 weeks of treatment (DeJesus et al., 2012; Sax et al., 2012).
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Dolutegravir
ViiV Healthcare, a joint venture between GlaxoSmithKline and Pfizer, developed
dolutegravir, a tricyclic carbamoyl pyridine, and introduced the drug as Tivicay (50 mg DTG) in
August 2013 (Ballantyne & Perry, 2013; Hajimahdi & Zarghi, 2016). One year later, Triumeq, a
combination of dolutegravir (50 mg), abacavir (600 mg), and lamivudine (300 mg), also received
FDA approval (Gohil, 2014). Due to the inclusion of abacavir, this single tablet regimen is only
available for HLA-B*5701 negative individuals (Greig & Deeks, 2015).
Dolutegravir was thought to be an improvement upon raltegravir, in terms of dosing
schedule (prior to the 1200 mg once-daily dose) ("Isentress Prescribing Information," 2017), and
elvitegravir, in terms of boosting (Molina et al., 2015). Although food does not seem to have a
clinically significant effect on drug absorption, meal fat content (low, moderate, or high) has
been shown to increase the area under the plasma concentration time curve (33%, 41%, and 66%,
respectively compared to fasting) ("Tivicay Prescribing Information," 2017). Apparent volume
of distribution was determined to be approximately 17.4 L with protein binding of nearly 99%
when administered as Triumeq (Greig & Deeks, 2015). Dolutegravir is principally metabolized
by UGT1A1; however, CYP3A enzymes produce a minor metabolite as well (Castellino et al.,
2013). A half-life of 14 hours has been seen with dolutegravir (Min et al., 2010). Unchanged
drug is excreted 53% in the feces with very little (<1%) in the urine; however, 31% of
metabolized dolutegravir is found in the urine ("Tivicay Prescribing Information," 2017).
Dolutegravir was also found to distribute into the cerebrospinal fluid (Greig & Deeks, 2015).
A meta-analysis of four randomized controlled trials comprised of treatment-naïve
individuals performed by Jiang et al. found that dolutegravir regimens were superior to efavirenz
(an NNRTI) and raltegravir based regiments in terms of safety and efficacy (Jiang et al., 2016).
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Nausea and headache were the most frequent adverse events associated with dolutegravir. When
dosed with dual NRTI regimens (abacavir/lamivudine or tenofovir disoproxil
fumarate/emtricitabine) in the SINGLE study, dolutegravir was shown to be superior to
efavirenz/tenofovir disoproxil fumarate/emtricitabine at 48 weeks of therapy (88% vs 81%,
respective viral suppression) (Walmsley et al., 2013). Similar results were observed at 96 weeks
(80% vs 72%, respectively) and at 144 weeks (71% vs 63%, respectively) (Greig & Deeks,
2015). In the FLAMINGO study, dolutegravir was compared to a PI and pharmacokinetic
booster combination, darunavir/ritonavir, (both dosed with NRTIs) for viral suppression at week
48 (90% vs 83%, respectively) and week 96 (80% vs 68%, respectively) (Molina et al., 2015).
Non-inferiority and superiority was conferred at 96 weeks. In the SPRING-2 study (a
randomized double-blind double dummy study), dolutegravir+NRTI was deemed non-inferior to
bid 400 mg raltegravir+NRTI at 48 weeks (88% vs 85% respective viral suppression) and
showed comparable safety and tolerability at 96 weeks (81% vs 76%) (Raffi, Jaeger, et al., 2013;
Raffi, Rachlis, et al., 2013). The SAILING study also determined that dolutegravir was not only
non-inferior to raltegravir, but superior as well with 71% viral suppression opposed to 64% in the
comparator group following 48 weeks of treatment (Cahn et al., 2013).
Pharmacogenetics
Pharmaceutical decision-making consists of several parameters; however, a relatively
recent addition to the puzzle is the utilization of pharmacogenetics, which is the subsection of
genetics dealing with pharmacokinetic and pharmacodynamic outcomes (Pouget, Shams, Tiwari,
& Muller, 2014). As such, metabolic enzymes have been shown to exhibit alteration when
genetic polymorphisms are present (Elens et al., 2013; Okubo et al., 2013; Wang, Guo,
Wrighton, Cooke, & Sadee, 2011). Recent data suggests that CYP3A4 shows reduced activity
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and/or expression with the presence of the CYP3A4*22 allele. Although one study did not find a
correlation with activity (Garcia-Martin et al., 2002), another study reported a polymorphism,
CYP3A4*1B, correlating with an increase in CYP3A4 activity (Klein & Zanger, 2013). The
presence of CYP3A5 polymorphism has also been suggested to relate to the metabolism of
CYP3A4 substrates (Wang & Sadee, 2012); thus CYP3A5*3 (rs776746) which yields a null
phenotype may be important to dolutegravir and elvitegravir metabolism (Elens et al., 2013).
CYP2D6 also has a large number of polymorphisms which influence enzyme activity (Khlifi,
Messaoud, Rebai, & Hamza-Chaffai, 2013). In a study by Ritchie et al., a polymorphism in the
ABCB1 gene, which encodes for p-glycoprotein (P-gp), was suggested to influence toxicity of a
P-gp substrate such as dolutegravir (Ritchie et al., 2006; "Tivicay Prescribing Information,"
2017). In a recent study by D’Avolio et al. (D'Avolio et al., 2014), a SNP (rs4149056) in organic
anion transport protein (OATP) 1B1, which interacts with cobicistat, was found to correlate with
changes in ritonavir plasma concentrations.
Specific Aims
Because polymorphisms in drug metabolizing enzymes, transporters, and/or receptors can
influence drug pharmacokinetics and thereby alter drug properties, we conducted an exploratory
pharmacogenetic analysis of INSTI regimens consisting of numerous SNPs included on the
iPLEX PGx ProPanel. We hypothesized that particular drug outcomes will be influenced by
pharmacogenetics. This hypothesis is proposed based on the following observations. First,
raltegravir and dolutegravir are primarily metabolized by UGT1A1 (Arab-Alameddine et al.,
2012; Castellino et al., 2013). Second, elvitegravir is metabolized by CYP3A4 (Olin et al.,
2012). Third, the expression of most enzymes is modulated by nuclear receptors (Coleman &
Wiley InterScience (Online service), 2010), which like the expression of many drug
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metabolizing enzymes and transporters, are influenced by genetic polymorphism (Michaud et al.,
2012). The genetic variability in the expression of enzymes and transporters may produce
alterations in drug pharmacokinetics, and consequently drug effects (Wyatt et al., 2012). The
following specific aims were designed to test our hypothesis: evaluate drug exposure in HIV-1
patients, document genetic polymorphisms, collect clinical outcomes, and perform association
analyses.
*Portions of this chapter were previously published in European Review for Medical and
Pharmacological Sciences (Murrell DE, Moorman JP, Harirforoosh S. Stribild: a review of
component characteristics and combination drug efficacy. European review for medical and
pharmacological sciences. 2015;19(5):904-14. PubMed PMID: 25807445.)
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Abstract
Integrase strand transfer inhibitors (INSTIs) have become integral in HIV treatment with close
monitoring of continued efficacy and tolerability. This exploratory study evaluated
polymorphism influence on drug exposure and tolerability. HIV+ adults (≥18yrs) receiving
INSTI-based regimens were recruited (n=88) and genotyped with an iPLEX PGx Panel. Genetic
variants within our population, underwent multiple regression with covariates [age, sex, BMI,
regimen (comprehensive group), regimen duration, and baseline variables (as required)] to detect
significant (p<0.05) association of concentration data and selected clinical data. With a median
age of 52.5 years (IQR 45.7-57.2) being predominately Caucasian (88.6%) and male (86.4%),
this exploratory study discovered that dolutegravir trough concentration was influenced by
selected single nucleotide polymorphisms (SNPs). In addition, several associations were
identified between variables and SNPs, when using INSTIs; however, clinical significance is
unknown. These exploratory findings require confirmation in larger studies which may also
investigate interaction mechanisms.
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Introduction
Over the past decade, HIV integrase strand transfer inhibitors (INSTIs) have moved to the
frontlines of antiretroviral therapy (1). Regarding three of the four approved INSTIs
(dolutegravir, elvitegravir, and raltegravir), each is frequently efficacious; however, variability in
regimen tolerability may be of concern(2). Dolutegravir was thought to be an improvement upon
raltegravir, in terms of reduced dosing frequency (prior to once-daily 1200 mg raltegravir) (3),
and elvitegravir, in terms of boosting necessity (4); however, elevated drug concentrations can be
problematic (5). In the case of elvitegravir, the drug concentration at the end of the dosing
interval at steady-state (Ctrough) seems related to outcomes (6, 7). The pharmacokinetics of
raltegravir have been shown to have intra- and inter-subject variation which may influence drug
outcomes (8). Thus, drug exposure play an important role in the use of these regimens.
Concurrent with the rise of the INSTIs, the field of personalized medicine has also gained
traction in the clinical realm. One method of informing pharmaceutical decision-making is the
integration of pharmacogenetics, the interaction of genetic information with drug
pharmacokinetics and outcomes. Recent data suggests that cytochrome P450 3A4 (CYP3A4), a
metabolizing enzyme of many drugs, including dolutegravir and elvitegravir, shows reduced
activity and/or expression with the presence of the CYP3A4*22 allele (rs35599367) (9-11).
Although a different study discovered such a correlation with activity (12), a further study
reported a polymorphism, CYP3A4*1B (rs2740574), correlated with an increase in CYP3A4
activity (13). The presence of CYP3A5 polymorphism has also been suggested to relate to the
metabolism of CYP3A4 substrates, such as elvitegravir, (14); thus SNPs such as CYP3A5*3
(rs776746) which yield a null phenotype may partially reduce metabolism (9). Drug transporters,
such as the ATP-binding cassette transporter B1 (ABCB1), also known as p-glycoprotein, have
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been suggested to influence toxicity of substrates (15). Dolutegravir and raltegravir, pglycoprotein substrates, may be adversely affected by changes in p-glycoprotein (16, 17). In this
study, we conducted an exploratory pharmacogenetic analysis of INSTI regimens, consisting of
numerous SNPs included on the iPLEX PGx Panel v1.0, to understand the influence of genetic
polymorphism on overall drug exposure and clinical tolerability.
Results
Subject Demographics
All HIV+ individuals receiving care at the East Tennessee State University (ETSU)
Center of Excellence (COE) for HIV/AIDS Care (n=341) were screened for this study. Overall
demographic characteristics, along with stratification by INSTI, are presented in Table 1. Of the
eligible subjects (n=216), eighty-eight HIV+ individuals (86.4% male) with a median age of 52.5
years were recruited. The primarily non-Hispanic Caucasian population presented with a mean
BMI of 26.2. Only 3 of the 88 subjects reported a missed dose within the two weeks prior to
sample collection. The majority (85/86) of subjects were virally suppressed (<20 RNA
copies/mL) or had a low-level viremia (below 60 RNA copies/mL) at or near sample collection;
while viral load data was not available for two subjects.
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Table 1: Subject demographics
Dolutegravir
(n=42)

Elvitegravir
(n=23)

Raltegravir
(n=23)

Total
(n=88)

Age in years, median (IQR)

53.0 (42.7 - 58.5)

50.0 (42.0 - 54.5)

53.0 (50.0 - 58.5)

52.5 (45.7 – 57.2)

Male, count (%)

37 (88.1%)

20 (87.0%)

19 (82.6%)

76 (86.4%)

Mean Body Mass Index (SD)

24.7 ± 4.8

29.1 ± 6.6

26.0 ± 5.1

26.2 ± 5.63

Black

5

3

0

8

White

36

19

23

78

Other

2

1

3

6

66.9 ± 39.0

80.8 ± 56.3

162.0 ± 77.3

95.4 ± 68.2

Race or ethnic group (All that apply)

Regimen Duration (weeks)

Pharmacogenetic Analysis
All samples had a call rate of ≥97%. The genotyping efficiency was greater than 95% for
all, but three SNPs (rs5030865, 77.7%; rs28371706, 57.4%; and rs1065411, 83.0%) which
showed low yield were not included in analysis. Of the remaining 175 SNPs on the panel, 86
were polymorphic within this population. SNPs were further excluded based on low minor allelic
frequency below 1%.
Drug Exposure
Mean dolutegravir Ctrough (n=23) was determined to be 764.13±401.66 ng/mL. When
stratified by genotype, the concentrations were associated with five SNPs as revealed in Table
2.Two CYP2D6 SNPs (rs1065852 and rs3892097) were shown to increase dolutegravir
concentration along with rs7294 in VKORC1. Meanwhile, rs4149056 and rs8192709 were
associated with decreases in dolutegravir concentration. Two of the associated SNPs, rs1065852
and rs3892097, were in linkage disequilibrium (LD) (r2=0.850). Although the Ctrough of
elvitegravir (n=15; 263.84±146.92 ng/mL) and raltegravir (n=6; 567.16±307.19 ng/mL) were
determined, no SNPs showed association with elvitegravir or raltegravir concentration following
multiple regression.

Table 2: SNPs significantly associated with drug concentration
Drug

Gene

SNP

Chromosome BPa

A1b

MAFc

HWEd

Beta (95% CI)e

p-value

Dolutegravir

CYP2D6

rs1065852

22

42526694

T

0.190

1.000

430.80 (149.40 — 712.20)

0.008

SLCOB1

rs4149056

12

21331549

C

0.095

1.000

-508.20 (-840.80 — -175.50)

0.009

CYP2D6

rs3892097

22

42524947

A

0.167

1.000

407.60 (102.50 — 712.60)

0.019

CYP2B6

rs8192709

19

41497274

T

0.060

1.000

-785.80 (-1422.00 — -149.80) 0.028

VKORC1

rs7294

16

31102321

A

0.452

0.984

230.30 (41.33 — 419.20)

a

b

c

d

e

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Beta
adjusted for covariates (sex, age, BMI, and regimen duration)

0.030

Hepatic Parameters
No group had mean alkaline phosphatase (ALP) levels outside the normal range of 30-125
U/L (18) (comprehensive group, 73.25±42.94 U/L; dolutegravir group, 69.94±24.30 U/L;
elvitegravir group, 85.39±72.57 U/L; and raltegravir group, 66.73±24.37 U/L). The difference in
mean ALP among the regimens was not significant (p=0.277). Table 3 shows that two SNPs
(rs2273697 and rs737865) reached a positive significant association with ALP levels across all
regimens. No SNPs reached multiple regression significance in the dolutegravir group. Seven
SNPs, two of which (rs9934438 and rs9923231) being in LD (r2=1), were associated with ALP
levels in elvitegravir-receiving individuals. The addition of minor alleles revealed increases of
ALP in six SNPs; while minor alleles in rs7294 were negatively associated with ALP level. The
raltegravir group had two SNPs (rs1045642 and rs17708472) yielded positive association with
ALP levels.

Table 3: SNPs significantly associated with ALP levels
BPa

A1b

MAFc

HWEd

Beta (95% CI)e

p-value

rs2273697 10

101563815

A

0.199

0.165

16.39 (2.75 — 30.03)

0.021

rs737865

22

19930121

C

0.301

0.406

17.27 (4.90 — 29.64)

0.008

Elvitegravir CYP2C8

rs1058930 10

96818119

G

0.043

1.000

228.60 (151.90 — 305.20)

<0.001

VKORC1

rs9934438 16

31104878

A

0.261

0.933

72.94 (25.48 — 120.40)

0.008

VKORC1

rs9923231 16

31107689

T

0.261

0.933

72.94 (25.48 — 120.40)

0.008

ABCC2

rs2273697 10

101563815

A

0.217

0.501

62.42 (18.29 — 106.50)

0.014

COMT

rs737865

22

19930121

C

0.196

0.329

69.59 (21.03 — 118.20)

0.013

VKORC1

rs7294

16

31102321

A

0.413

0.799

-55.92 (-106.70 — -5.17)

0.046

CYP2C9

rs1799853 10

96702047

T

0.109

1.000

91.44 (7.08 — 175.80)

0.050

rs1045642 7

87138645

T

0.478

0.166

17.49 (3.21 — 31.78)

0.032

rs17708472 16

31105353

A

0.239

1.000

16.53 (2.90 — 30.15)

0.033

Drug

Gene

SNP

All

ABCC2
COMT

Raltegravir ABCB1
VKORC1
a

b

Chromosome

c

d

e

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Beta for ALP levels
adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), integrase inhibitor duration, and baseline ALP]

The elvitegravir group (32.48±28.25 U/L) had a mean alanine aminotransferase (ALT)
level in the upper normal range (0-40 U/L) (18); while the other groups, comprehensive,
dolutegravir, and raltegravir, showed 26.81±20.05 U/L, 24.44±16.41 U/L, and 25.32±15.18 U/L,
respectively. Mean ALT among the regimens did not show significant differences (p=0.285).
Two SNPs (rs2282143 and rs1048943) were determined to have a positive association with ALT
levels (Table 4) when all regimens were combined. There were no associated SNPs after
dolutegravir stratification. Five SNPs, four (rs9934438, rs9923231, rs2282143, and rs1048943)
with a positive beta and one (rs7294) with a negative beta, were associated with ALT in terms of
elvitegravir-receiving patients. As previously noted, rs9934438 and rs9923231 were in LD along
with rs2282143 and rs1048943 (r2=1). Additionally, raltegravir-grouped samples presented two
associated SNPs, one negative (rs165599) and one positive (rs34059508) when analyzed for
ALT levels.

Table 4: SNPs significantly associated with ALT levels
Drug

Gene

SNP

Chromosome BPa

A1b

MAFc

HWEd

Beta (95% CI)e

p-value

ALL

SLC22A1

rs2282143

6

160557643

T

0.028

0.113

29.77 (17.01 — 42.53)

<0.001

CYP1A1

rs1048943

15

75012985

G

0.045

0.306

19.01 (7.41 — 30.61)

0.002

Elvitegravir VKORC1

rs9934438

16

31104878

A

0.261

0.933

28.97 (11.68 — 46.25)

0.005

VKORC1

rs9923231

16

31107689

T

0.261

0.933

28.97 (11.68 — 46.25)

0.005

VKORC1

rs7294

16

31102321

A

0.413

0.799

-24.96 (-40.60 — -9.32)

0.006

SLC22A1

rs2282143

6

160557643

T

0.065

0.133

25.39 (6.00 — 44.77)

0.021

CYP1A1

rs1048943

15

75012985

G

0.065

0.133

25.39 (6.00 — 44.77)

0.021

rs165599

22

19956781

G

0.283

1.000

-10.65 (-18.17 — -3.13)

0.014

160575837

A

0.065

1.000

18.34 (4.50 — 32.17)

0.020

Raltegravir COMT
SLC22A1
a

rs34059508 6
b

c

d

e

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Beta for ALT levels
adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), integrase inhibitor duration, and baseline ALT levels]

Mean aspartate aminotransferase (AST) levels (comprehensive group, 24.79±17.24 U/L;
dolutegravir group, 23.49±10.38 U/L; elvitegravir group, 29.48±29.19 U/L; and raltegravir
group, 22.32±8.48 U/L) were each within the high end of the 3-44 U/L normal range (18). No
significant difference (p=0.307) was detected among the AST levels between the regimens. The
four AST level-SNP associations (rs9934438, rs9923231, rs2273697, and rs4680), each being
positive, across regimens are found in Table 5. The VKORC1 SNPs (rs934438 and rs9923231)
were found to be in complete LD (r2=1). Dolutegravir grouping did not yield association between
SNPs and AST values. AST levels were associated SNPs within four genes (VKORC1, CYP2C8,
ABCC2, and CYP2E1) across elvitegravir regimens with only two SNPs in LD (r2=1).
Raltegravir AST levels were deemed to be associated with three SNPs (rs2231142 and
rs9282861 being positive and rs4244285 being negative).

Table 5: SNPs significantly associated with AST levels
Chromosome BPa

b

c

Drug

Gene

SNP

ALL

VKORC1

rs9934438

16

31104878

A

0.318

VKORC1

rs9923231

16

31107689

T

ABCC2

rs2273697

10

101563815

COMT

rs4680

22

Elvitegravir VKORC1

rs9934438

VKORC1

d

e

Beta (95% CI)

p-value

0.723

8.43 (2.86 — 14.00)

0.004

0.318

0.723

8.43 (2.86 — 14.00)

0.004

A

0.199

0.165

7.42 (1.44 — 13.39)

0.017

19951271

G

0.455

0.534

6.19 (0.82 — 11.55)

0.027

16

31104878

A

0.261

0.933

33.24 (16.68 — 49.80)

0.001

rs9923231

16

31107689

T

0.261

0.933

33.24 (16.68 — 49.80)

0.001

CYP2C8

rs1058930

10

96818119

G

0.043

1.000

82.01 (44.06 — 120.00)

0.001

ABCC2

rs2273697

10

101563815

A

0.217

0.501

30.12 (13.76 — 46.47)

0.002

VKORC1

rs7294

16

31102321

A

0.413

0.799

-28.99 (-47.70 — -10.28) 0.008

CYP2E1

rs2070673

10

135340567

A

0.239

1.000

-29.60 (-56.83 — -2.36)

0.049

Raltegravir ABCG2

rs2231142

4

89052323

A

0.109

0.429

8.53 (1.95 — 15.12)

0.025

CYP2C19

rs4244285

10

96541616

A

0.174

1.000

-6.39 (-11.75 — -1.03)

0.036

SULT1A1

rs9282861

16

28617514

A

0.304

0.619

6.20 (0.94 — 11.46)

0.038

a

b

c

A1

d

MAF

HWE

e

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Beta for AST levels
adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), integrase inhibitor duration, and baseline AST levels]

Renal Parameters
All mean blood urea nitrogen (BUN) levels (comprehensive group, 15.10±5.11 mg/dL;
dolutegravir group, 14.66±4.55 mg/dL; elvitegravir group, 15.00±4.32 mg/dL; and raltegravir
group, 16.05±6.74 mg/dL) were discovered as normal (8-21 mg/dL) (18). As mean BUN among
the regimens was similar, no significant changes (p=0.592) were found. Numerous SNPs were
associated with BUN levels (Table 6) in the comprehensive group; while no associations were
found with dolutegravir. The top two SNPs in the comprehensive group rs4149117 and
rs7311358 were found to be in LD (r2=1); the third (rs1799930) and fourth (rs1041983) SNPs
were highly related (r2=0.882) as well; the four SNPs in SLC15A2 were also in high LD
(rs1143671 vs rs2293616/rs2257212, r2=1; rs1143671 vs rs1143672, r2=0.978); and the
VKORC1 gene SNPs as mentioned in the AST section earlier. Elvitegravir associations were
found between BUN levels and six SNPs. Several SNPs were discovered to be significant in
association with raltegravir-dosed subject BUN levels. The LD was similar to the elvitegravir
group with rs2293616 vs rs1143671/rs2257212 yielding r2=1 and rs2293616 vs rs1143672
showing r2=0.912; however, the UGT2B7 SNPs (rs7662029 and rs7668258) in this group were
also in LD (r2=1).

Table 6: SNPs significantly associated with BUN levels
Drug

Gene

SNP

Chromosome BPa

A1

ALL

SLCO1B3

rs7311358

12

21015760

G

0.205

0.014

1.65 (0.43 — 2.86)

0.010

NAT2

rs1799930

8

18258103

A

0.335

0.192

-1.21 (-2.30 — -0.12)

0.033

NAT2

rs1041983

8

18257795

T

0.364

0.169

-1.16 (-2.23 — -0.10)

0.036

CYP2D6

rs1080985

22

42528382

G

0.216

0.337

2.00 (0.53 — 3.46)

0.009

VKORC1

rs7294

16

31102321

A

0.455

0.502

1.62 (0.41 — 2.84)

0.011

COMT

rs4680

22

19951271

G

0.455

0.534

-1.51 (-2.64 — -0.37)

0.011

SLC15A2

rs2293616

3

121641693

C

0.483

0.966

1.29 (0.09 — 2.48)

0.039

SLC15A2

rs2257212

3

121643804

G

0.483

0.966

1.29 (0.09 — 2.48)

0.039

SLC15A2

rs1143671

3

121647286

C

0.483

0.966

1.29 (0.09 — 2.48)

0.039

SLC15A2

rs1143672

3

121648168

G

0.477

0.804

1.29 (0.09 — 2.48)

0.039

VKORC1

rs9934438

16

31104878

A

0.318

0.723

-1.27 (-2.48 — -0.06)

0.044

VKORC1

rs9923231

16

31107689

T

0.318

0.723

-1.27 (-2.48 — -0.06)

0.044

a

b

c

d

b

MAF

c

HWE

d

Beta (95% CI)

e

e

p-value

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Beta for BUN levels
adjusted for covariates [sex, age, BMI, integrase inhibitor, integrase inhibitor duration, and baseline BUN levels]

Table 6: SNPs significantly associated with BUN levels (continued)
Drug

SNP

Chromosome BPa

A1b

MAFc

HWEd

Beta (95% CI)e

p-value

rs1080985

22

42528382

G

0.217

0.575

4.48 (1.58 — 7.38)

0.008

COMT

rs4680

22

19951271

G

0.391

0.329

-3.35 (-5.23 — -1.47)

0.003

CYP2C9

rs28371685

10

94981224

T

0.022

1.000

8.84 (1.74 — 15.93)

0.027

COMT

rs737865

22

19930121

C

0.196

0.329

-3.02 (-5.57 — -0.45)

0.035

VKORC1

rs7294

16

31102321

A

0.413

0.799

3.85 (0.47 — 7.23)

0.040

CYP2C8

rs1058930

10

96818119

G

0.043

1.000

-7.10 (-13.50 — -0.70)

0.045

CYP1A1

rs1048943

15

75012985

G

0.022

1.000

10.52 (1.35 — 19.69)

0.044

SLC15A2

rs1143672

3

121648168

G

0.370

1.000

3.75 (0.54 — 6.95)

0.041

SLC15A2

rs2293616

3

121641693

C

0.391

1.000

3.75 (0.54 — 6.95)

0.041

SLC15A2

rs2257212

3

121643804

G

0.391

1.000

3.75 (0.54 — 6.95)

0.041

SLC15A2

rs1143671

3

121647286

C

0.391

1.000

3.75 (0.54 — 6.95)

0.041

UGT2B15

rs1902023

4

69418747

T

0.435

0.049

-3.82 (-6.64 — -0.99)

0.021

UGT2B7

rs7662029

4

69961912

A

0.413

0.799

3.42 (0.74 — 6.10)

0.028

UGT2B7

rs7668258

4

69962078

T

0.413

0.799

3.42 (0.74 — 6.10)

0.028

Gene

Elvitegravir CYP2D6

Raltegravir

a

b

c

d

e

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Beta for BUN
levels adjusted for covariates [sex, age, BMI, integrase inhibitor, integrase inhibitor duration, and baseline BUN levels]

All estimated glomerular filtration rates (eGFR) were under the normal range of greater
than 90 mL/min/1.73 m2 (comprehensive group, 63.45±16.54 mL/min/1.73 m2; dolutegravir
group, 61.88±15.97 mL/min/1.73 m2; elvitegravir group, 63.43±15.73 mL/min/1.73 m2; and
raltegravir group, 66.41±18.67 mL/min/1.73 m2). Regimen differences in mean eGFR were not
significant (p=0.590). Exploration of eGFR uncovered three SNPs (Table 7) that presented
significant positive association across regimens (rs4986989, rs34130495, and rs3213619).
Significance was not found concerning eGFR levels in dolutegravir dosing. In elvitegravir group
analysis, five different SNPs were associated following multiple regression; however,
rs28371686 and rs28399454 as well as rs4149117 and rs7311358 were in strong LD (r2=1). Each
SNP, apart from rs717620, was associated with a decrease of eGFR with each minor allele.
Evaluation of the raltegravir group identified no SNPs that were associated with eGFR.

Table 7: SNPs significantly associated with eGFR
Drug

Gene

SNP

Chromosome BPa

A1b

MAFc

HWEd

Beta (95% CI)e

p-value

ALL

NAT1

rs4986989

8

18222008

T

0.023

1.000

14.81 (2.65 — 26.97)

0.019

SLC22A1

rs34130495

6

160560824

A

0.017

1.000

13.01 (0.83 — 25.19)

0.039

ABCB1

rs3213619

7

87230193

C

0.028

1.000

10.20 (0.27 — 20.12)

0.048

Elvitegravir CYP2C9

rs28371686

10

96741058

G

0.022

1.000

-20.67 (-36.33 — -5.01) 0.019

CYP2A6

rs28399454

19

41351267

A

0.022

1.000

-20.67 (-36.33 — -5.01) 0.019

SLCO1B3

rs4149117

12

21011480

T

0.283

0.069

-5.08 (-9.27 — -0.89)

0.029

SLCO1B3

rs7311358

12

21015760

G

0.283

0.069

-5.08 (-9.27 — -0.89)

0.029

ABCC2

rs717620

10

101542578

A

0.130

1.000

7.74 (0.83 — 14.64)

0.041

a

b

c

d

e

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Beta for eGFR
adjusted for covariates [integrase inhibitor (in All group), integrase inhibitor duration, and baseline eGFR]

Discussion
The purpose of this study was to examine the effects of genetics, adjusted for individual
patient characteristics, on systemic INSTI exposure along with hepatic and renal tolerability. We
found that in this population of primarily Caucasian male subjects that the majority were virally
suppressed and tolerating their respective regimens (Table 1).
The concentration of dolutegravir we found was below the geometric means previously
reported as 1070 ng/mL and 1500 ng/mL for dolutegravir (19) and
dolutegravir/abacavir/lamivudine (20), respectively. Based on reported geometric mean
elvitegravir concentrations of 490 ng/mL, in the formulation containing tenofovir disoproxil
fumarate (21), and 290 ng/mL, in the tenofovir alafenamide formulation (22), our mean
concentration was somewhat less. Our average raltegravir Ctrough concentration of 567.16 ng/mL
was much higher than the geometric mean 142 nM (approximately 68.52 ng/mL) previously
reported (23). The reductions seen in our study may have several explanations ranging from
subject reported dosing to differences in food intake (6, 24).
None of the SNP-associations that we found with dolutegravir have been reported
elsewhere (Table 2). Additionally, none of these genes are known to interact with dolutegravir.
Concerning ABCB1 SNP (rs1045642), an absence of correlation has been reported with
dolutegravir plasma concentration (25) and this supports the absence of the association in seen in
our study. The high variability within dolutegravir concentrations coupled with small sample size
and distribution of genotypes necessitate confirmation, but the presence of associations may
serve as a road map to future discovery. These SNP-associations would be very important to
confirm as the effects are rather large (Table 2).

The absence of any associations in the elvitegravir and raltegravir groups may be a
function of further reduced sample size through inability to detect drug concentrations.
Alternatively, the reason could be a property of the selected SNPs. UGT1A1*28/*28 (AA in
rs8175347) has been shown to yield higher raltegravir in blood (26); UGT1A1*28 has produced
a mild reduction in elvitegravir clearance (27); and homozygous UGT1A1*28 has also been
shown to increase dolutegravir exposure (28). This SNP; however, was not included on the
panel. Also some of the included SNPs, 1128503, rs2032582, rs1045642, and rs2231142, have
previously been found to not change raltegravir Ctrough, but they did find alterations in peak
concentrations (25). We would not have seen this effect as we only took Ctrough.
In this study, no regimen grouping of subjects showed a mean ALP level outside the
normal range which suggests that these associations may not be clinically significant unless other
factors are involved. In a previous study by Tebas et al., dolutegravir, when co-administered with
abacavir and lamivudine, was shown to increase bone-specific alkaline phosphatase by a 50%
change from baseline following 144 weeks of administration (29). Additionally, when switching
from an efavirenz-based regimen to a raltegravir-based regimen, serum ALP was significantly
decreased in the raltegravir group compared to an efavirenz group at 24 weeks (30). In our study,
the alkaline phosphatase was nonspecific; however, an increase in the bone-specific form would
elevate the nonspecific form. It seems that none of the SNPs, which showed significance in this
study, have been previously reported to influence ALP levels (Table 3). Although many showed
high variability, most, apart from rs7294, found that adding a minor allele would tend to increase
ALP levels. The genes identified with ALP levels in this study include transporters (ABCC2)
and metabolizing enzymes (CYP2C8) (31). Thus, these changes may occur through drug
remaining in hepatocytes rather than being pumped out.
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ALT levels were not significantly altered among treatment groups. None of the ALTSNP associations (Table 4) we presented have been previously reported to the best of our
knowledge. A study conducted in a Japanese population did find that female subjects with
homozygous A alleles in rs4680 had lower odds ratios, when using logistic regression, of having
elevated ALT levels compared to both homozygous G alleles and heterozygous individuals with
a similar trend was found in males aged 45-54 (32). We did not see an association with rs4680 in
any of our groups for ALT levels. In our study, the transporter SLC22A1 appeared frequently
which may indicate, as noted earlier with ALP, that drug accumulation may play a role in these
associations.
Although none of the mean AST levels were above normal, the elvitegravir group had a
very high variation. This variation may have inflated the betas for the multiple linear regression
results at least for the comprehensive and the elvitegravir groups. Otherwise none of the
presented SNPs (Table 5) have been reported elsewhere in relation to AST levels. As suggested
with ALP and ALT, drug accumulation or lack thereof may explain the minor alterations in
hepatic function enzymes. Overall, these regimens appear to be relatively well tolerated in terms
of hepatic outcomes. However, some of the polymorphisms may have a large effect on respective
marker levels. Thus, these may need to be monitored closely in certain patients.
In regard to renal effects, many SNP associations were found with BUN levels (Table 6);
however, most effects were minor. There were a large number of SNPs in LD within these
groupings which lowers the number of useful polymorphisms; however, these SNPs have not
been previously identified as relating to BUN. Even if these SNPs associations are confirmed,
the likelihood of clinical significance is small unless other problem factors are present.
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Mean eGFR was lower than normal across all groups; however, this is common in those
receiving antiretrovirals. While eGFR did not seem to be related to dolutegravir or raltegravir
alone, the three SNPs in the comprehensive group seemed to improve renal function (Table 7).
Meanwhile, the associated SNPs found in elvitegravir each lowered eGFR. These may need to be
examined more closely to protect against renal insufficiency. As all of the elvitegravir groups
contained a form of tenofovir, especially tenofovir disoproxil fumarate, as well as cobicistat,
these lower values may be a function of renal damage or creatinine clearance changes (7, 33). In
addition, alterations in the movement of drugs in renal tubular cells may have contributed to the
associations identified.
The strong LD of certain SNPs in this population would allow for the use of one SNP to
cover the presence of both if r2 equals 1, which may be useful in the reduction of redundant
genotyping. In future studies which seek to analyze these exploratory associations, SNPs which
show LD may need to undergo haplotype analysis to further understand associations.
This study had a few limitations. The first being the low sample size, in terms of regimen
group size and the occurrence of different alleles, which may have influenced study outcomes.
Another limitation is the relatively homogenous population, predominately Caucasians which
may prevent analysis of SNPs that occur more frequently in different races; however, population
specific SNPs may be examined in greater numbers.
In conclusion, we determined that several SNPs found on the iPLEX panel were
significantly associated with various patient outcomes. The large number of previously
unreported associations may be due to the absence of clinical significance which may have
precluded publication. More studies are needed, preferably in a larger population to determine
the clinical applicability of our findings.
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Methods
Subject recruitment
All personnel, involved in patient contact and/or private health information use, received
the necessary training through the Collaborative Institutional Training Initiative program and
various other programs for ETSU/Veterans Affairs (VA) Medical Campus Institutional Review
Board (IRB) approval. Recruitment for this observational study was conducted between July
2015 and February 2017. Those individuals, being HIV-1 positive, who met the inclusion criteria
(≥18 years old, non-pregnant, and receiving an INSTI regimen) were contacted by phone.
Interested subjects were advised of a requisite regimen dosing schedule which would allow for
the capture of the Ctrough required for this study without influencing antiretroviral efficacy.
Informed consent was obtained in the presence of at least one investigator and witness. A review
of subject electronic health records was also performed. Subjects were compensated with a gift
card, with documentation of receipt, at the completion of study participation.
Dolutegravir regimens consisted of the single tablet regimen of dolutegravir (50
mg)/abacavir (600 mg)/lamivudine (300 mg), dolutegravir (50 mg) plus tenofovir disoproxil
fumarate (300 mg)/emtricitabine (200 mg), or dolutegravir (50 mg) plus tenofovir alafenamide
(25 mg)/emtricitabine (200 mg). Subjects on an elvitegravir regimen received one of two once-aday forms [elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir disoproxil fumarate (300
mg)/emtricitabine (200 mg) or elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir alafenamide
(10 mg)/emtricitabine (200 mg)]. Raltegravir was given twice-a-day concurrently with once-aday tenofovir disoproxil fumarate (300 mg)/emtricitabine (200 mg) or tenofovir alafenamide (25
mg)/emtricitabine (200 mg). A form of the tenofovir/emtricitabine background was used in over
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67% over subjects. Other antiretrovirals, such as protease inhibitors, were included in some
patients. Background regimens were not included in analysis.
Clinical Tolerability Analysis
Baseline values for hepatic and renal parameters were taken at the closest available point
prior to starting the regimen of interest; while current parameters were taken from the closest
possible point relative to sample collection. Sample collection and previous dosing times were
recorded in the questionnaire. Estimated glomerular filtration rate (eGFR) was calculated using
the 2009 Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) based upon plasma
creatinine. Comparison between regimens was conducted using one-way ANOVA with SPSS 25.
Drug Exposure Analysis
The Ctrough measurement has been used in previous studies with success and is less
invasive than traditional inpatient pharmacokinetic sampling (34, 35). Trained phlebotomists
collected whole blood sample (20 mL) at the end of respective regimen dosing intervals (24
hours for dolutegravir and elvitegravir as opposed to 12 hours for raltegravir). Plasma, for
pharmacokinetic analysis, and remaining cells, for genetic testing, were separated then placed at
-80 °C until analysis.
Samples were analyzed using an LC-MS method developed by Simiele et al. with
modifications (36). Briefly, a standard curve ranging from 10 ng/mL to 1,500 ng/mL was created
for drugs of interest from respective stock solutions in a 50:50 ratio of acetonitrile and water,
using blank human plasma (Innovative Research Inc Novi, MI). Verapamil, a drug which no
subject was concurrently receiving, was used as the internal standard in acetonitrile and 1%
formic acid in water (80:20). Pharmacokinetic samples (1 mL) underwent pH viral inactivation
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over a period of 1 hr at ambient temperature (23 °C) at a pH of 4, achieved using the addition of
100 µL of 1M HCL (37). One hundred microliters of internal standard were added then samples
were vortex mixed. Sample (200 µL) and 0.1% formic acid in acetonitrile (600 µL) were
aspirated in Ostro pass-through sample preparation 96-well plates (Waters Corporation, Milford,
MA). Collected samples underwent direct chromatography with a Waters X-Select HSS T3
column (150 x 4.6 mm, 3.5 micron) and a gradient of 0.1% formic acid in water (A) and 0.1%
formic acid in acetonitrile (B) (5-100 %). Mass spectrometric detection was achieved using
direct MS/MS channels for each drug, specific to their [M+H]+ ion. All solvents used for LCMS/MS analysis were of LC-MS Grade from Honeywell-Burdick and Jackson (Muskegon, MI).
Stock chemicals were purchased from Chemscene (Monmouth Junction, NJ).
Pharmacogenetic Analysis
A Sequenom iPLEX® ADME PGx Panel v1.0 (Sequenom, San Diego, CA) comprised of
assays for numerous genetic areas of interest, was used to evaluate the genetic profile of each
subject. DNA extraction and genotyping were performed at the Vanderbilt Technologies for
Advanced Genomics (VANTAGE) according to manufacturer specifications. Briefly, following
extraction from whole blood (Autopure LS, QIAGEN, Hilden, Germany), DNA was amplified
via PCR then free nucleotides were dephosphorylated. The iPLEX Gold reaction, being the
addition of a primer to the site of interest which is then extended by one nucleotide based on
genotype, was conducted. A MassARRAY® Analyzer returned subject alleles and the
MassARRAY Typer was used to determine genotype call rates. Hardy-Weinberg equilibrium
(HWE), minor allele frequency (MAF), and pairwise linkage disequilibrium (LD) statistics (r2)
were assessed using HAPLOVIEW software (38).
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SNPs are represented with the more frequent allele in the specific sampling being
identified as the reference; while the less frequent allele was identified as the minor allele
(reference allele>minor allele). Subject genotypes were analyzed using the additive genetic
association model. As such the dosage of minor allele was considered to have an additive effect
for example homogenous major alleles were coded as 1, heterogenous alleles as 2, and
homogenous minor alleles as 3. Then, to test for association with quantitative traits, multiple
linear regression, with the inclusion of covariates [age, sex, BMI, regimen (in the across regimen
group), regimen duration, and baseline variables (as required)], were performed by PLINK v1.07
to obtain the regression coefficient and p-value (39). Correction for multiple testing was not
conducted due to the exploratory nature of this study (40). Subject information, following deidentification, was uploaded into the ETSU version of REDCap (41).
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Study Highlights
o What is the current knowledge on the topic?
Pharmacogenetics play an important role in selected outcomes of drug dosing.
o What question did this study address?
This study sought to explore the relationship of selected single nucleotide polymorphisms
(SNPs) with drug exposure as well as respective patient hepatic and renal effects in subjects
receiving HIV integrase strand transfer inhibitors (INSTIs).
o What does this study add to our knowledge?
Several SNPs were identified that had previously been unrelated to clinical variables in INSTIs.
This exploratory study seeks to slightly expand the frame through which researchers are looking
to promote new lines of inquiry.
o How might this change clinical pharmacology or translational science?
The associations found in this study may spark interest in otherwise uncritically explored
genomic areas. If these results are supported and expanded in larger trials, new suggestions
and/or precautions for INSTI dosing may be developed.
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Abstract
Dolutegravir, elvitegravir, and raltegravir, are widely utilized HIV integrase strand transfer
inhibitors (INSTIs). As side effect occurrence varies among patients receiving these drugs, we
investigated the role of several single nucleotide polymorphisms (SNPs) in subject-reported
adverse events. SNPs underwent multiple logistic regression for association (p<0.05) with binary
traits including central nervous system-related (abnormal dream, anxiety, fatigue, headache, and
insomnia) and gastrointestinal-related (diarrhea and nausea) adverse events adjusted for age, sex,
BMI, and regimen duration along with specific regimen in the comprehensive group (included all
patients). HIV+ adults (≥18 years old) receiving an INSTI were recruited (n=88). Abnormal
dream occurrence was found to be associated (p=0.028) with regimen-received. Additionally,
several SNPs were found to be associated with adverse event profiles primarily in the
comprehensive group. In conclusion, the associations found in this study strengthen the need for
further assessment, within the HIV positive population, of factors contributing to unfavorable
patient outcomes.
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Introduction
After nearly four decades, the human immunodeficiency virus (HIV) remains a high
priority in scientific research with thousands of new infections occurring each day adding to the
upward of 36 million HIV positive individuals worldwide (1). Current antiretroviral therapy is
highly effective in reducing plasma HIV viral load; however, several factors may impact the
efficacy and tolerability of antiretrovirals (2-4). Of the four currently available integrase strand
transfer inhibitors (INSTIs), clinical experience is greatest with dolutegravir, elvitegravir, and
raltegravir (5). Nausea and headache are the most frequent adverse events associated with
dolutegravir (6) with neuropsychiatric adverse events in general having been reported as reasons
for changing regimens (7). Meanwhile, elvitegravir and raltegravir also show central nervous
system (CNS) as well as gastrointestinal (GI) adverse events (8-10).
While many factors contribute to the patient outcomes, variations in the genetic make-up
of an individual may also alter the behavior of some drugs resulting in differences in both
efficacy and toxicity (11). For example, reduction in the activity and/or expression of metabolic
enzymes or transporters may greatly influence drug pharmacokinetics and thereby alter patient
outcomes (12-14). As adverse effect profiles often play an important role in the selection and
maintenance of antiretroviral therapy, we sought to identify associations between the occurrence
of CNS and GI adverse events with single nucleotide polymorphisms (SNPs) in an exploratory
cohort of patients receiving currently available INSTIs.
Results
Eighty-eight HIV positive adults (comprehensive group), differentiated by INSTI
(regardless of nucleoside backbone), dolutegravir group (n=42, 88.1% male), elvitegravir group
(n=23, 87.0% male), or raltegravir group (n=23, 82.6% male) were recruited. Further
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demographic information has been previously reported by our group (15). Adverse event
occurrence stratified by genotype, in significant associations, are shown in supplemental tables.
Central Nervous System Adverse Events
Abnormal Dream Occurrence. With a significant association (p=0.028) between regimen
and adverse event occurrence, abnormal dreams were reported more frequently in the raltegravir
group (30.4%) compared with either the elvitegravir (4.3%) or the dolutegravir group (9.5%).
One SNP (rs1143672) was determined to have a protective (decreased occurrence likelihood)
association with abnormal dreams in the comprehensive group (Table 1). Dolutegravir and
elvitegravir stratification yielded no significant SNPs; while one SNP (rs1128503) was
associated with decreased abnormal dream occurrence in the raltegravir group when minor
alleles were present.
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Table 1: SNPs significantly associated with CNS adverse event occurrence
CNS
Drug
adverse event

Gene

Abnormal
Dreams

SLC15A2 rs1143672 3

ALL

Fatigue

a

Chromosome BPa

A1

b

MAF

c

HWE

d

OR (95% CI)

e

p-value

121648168 G

0.477

0.804

0.31 (0.11 — 0.93)

0.037

rs1128503 7

87179601 T

0.370

0.644

0.07 (0.01 — 0.98)

0.049

SLC15A2 rs1143672 3

121648168 G

0.477

0.804

0.45 (0.22 — 0.92)

0.028

VKORC1 rs9934438 16

31104878 A

0.318

0.723

2.08 (1.01 — 4.30)

0.048

VKORC1 rs9923231 16

31107689 T

0.318

0.723

2.08 (1.01 — 4.30)

0.048

ABCB1

87179601 T

0.358

0.764

0.33 (0.15 — 0.76)

0.009

CYP2E1 rs2070673 10

135340567 A

0.210

1.000

2.62 (1.14 — 6.01)

0.023

UGT2B15 rs1902023 4

69418747 T

0.494

0.181

2.08 (1.10 — 3.93)

0.025

Raltegravir CYP2D6 rs3892097 22

42524947 A

0.152

1.000

20.59 (1.51 — 280.40) 0.023

CYP2D6 rs1065852 22

42526694 T

0.174

1.000

16.40 (1.21 — 222.90) 0.036

SLC22A2 rs316019 6

160670282 T

0.109

1.000

17.83 (1.07 — 297.10) 0.045

Raltegravir ABCB1
Anxiety

SNP

ALL

ALL

b

rs1128503 7

c

d

e

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Odds ratio for
CNS adverse event occurrence adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), and integrase inhibitor
duration]

Table 1: SNPs significantly associated with CNS adverse event occurrence (continued)
CNS
Drug
adverse event

Gene

SNP

Chromosome BPa

Headache

GSTP1

rs1695

11

67352689 G

0.347

1.000

3.53 (1.46 — 8.55)

0.005

SLCO1B1 rs2306283 12

21329738 G

0.477

0.499

0.42 (0.19 — 0.92)

0.031

ABCB1

rs3213619 7

87230193 C

0.028

1.000

18.37 (1.86 — 181.90) 0.013

VKORC1

rs9934438 16

31104878 A

0.318

0.723

2.70 (1.14 — 6.38)

0.024

VKORC1

rs9923231 16

31107689 T

0.318

0.723

2.70 (1.14 — 6.38)

0.024

Insomnia
a

ALL

ALL

b

c

d

A1

b

MAF

c

HWE

d

OR (95% CI)

e

e

p-value

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Odds ratio for
CNS adverse event occurrence adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), and integrase inhibitor
duration]

Anxiety Occurrence. Anxiety was reported in 29.5% of the comprehensive grouping;
while dolutegravir, elvitegravir and raltegravir groups presented with 33.3%, 17.4%, and 34.8%,
respectively. No significant interaction was found between regimen and anxiety occurrence
(p=0.368). In the comprehensive group, three SNPs, one protective (rs1143672) and two
increasing occurrences (rs9934438 and rs9923231), showed association with increased anxiety
occurrence (Table 1). Additionally, rs99234438 was in LD (r2=1.00) with rs9923231. When
regimens were tested as individual groups, there were no significantly associated SNPs.
Fatigue Occurrence. The occurrence of fatigue was frequent in each of the groups
(comprehensive; 33.0%; dolutegravir; 33.3%; elvitegravir, 30.4%; and raltegravir; 34.8%). As
such, no association was found between fatigue and regimen (p=1.000). Three SNPs, rs1128503
(decreased occurrence), rs2070673 (increased occurrence) , and rs1902023 (increased
occurrence), were associated with fatigue (Table 1) in the comprehensive group. Concerning the
dolutegravir and elvitegravir patients, fatigue occurrence was not associated with any SNPs
following multiple logistic regression. Raltegravir regimen grouping revealed three SNP
associations (rs3892097, rs1065852, and rs316019) with increased fatigue occurrence.
Headache Occurrence. Headaches occurred most frequently in the dolutegravir group
(33.3%) followed by the raltegravir group (17.4%) then the elvitegravir group (8.7%) with
overall occurrence being 22.7% of all patients. No association (p=0.066) was determined
between regimen and occurrence. While no logistic associations were found among the
individual regimens, three SNP-headache occurrence associations (Table 1) were discovered in
the comprehensive group. These ranged to from decreasing occurrence (rs3213619) to slight
elevation (rs1695) to larger increased frequency of occurrence (rs3213619).

Insomnia Occurrence. Insomnia was reported in 19.3% of patients overall which was
matched well with the 19.0% seen in dolutegravir. Meanwhile, elvitegravir and raltegravir
demonstrated differing rates with 8.7% and 30.4%, respectively. No association (p=0.190) was
determined to exist through Fisher’s exact testing. As shown in Table 1, one gene contained
SNPs (rs9934438 and rs9923231) which, when analyzed across regimens in the comprehensive
group, were significantly associated with increased insomnia occurrence. As noted earlier the
SNPs, rs9934438 and rs9923231, were in LD (r2=1.00). Individual drug groups showed no
associations.
Gastrointestinal adverse events
Diarrhea Occurrence. With an overall occurrence in 29.5% of patients, dolutegravir,
elvitegravir, and raltegravir grouping yielded 30.9%, 26.1%, and 30.4%, respectively. As the
presence of diarrhea was rather evenly distributed among groups, no association (p=0.955)
between this adverse event and regimen was found. One SNP (rs4680) exhibited a protective
association in the comprehensive group (Table 2); meanwhile, no other diarrhea-SNP
associations were found.

63

Table 2: SNPs significantly associated with GI adverse event occurrence
GI Adverse
Event

Drug

Gene

SNP

Chromosome BPa

Diarrhea

ALL

COMT

rs4680

22

19951271 G

0.455

0.534

0.42 (0.19 — 0.91)

0.027

Nausea

ALL

GSTP1

rs1695

11

67352689 G

0.347

1.000

2.82 (1.09 — 7.29)

0.033

NAT2

rs1208

8

18258316 G

0.398

0.447

2.64 (1.07 — 6.50)

0.034

a

b

c

d

A1

b

MAF

c

HWE

d

OR (95% CI)

e

e

p-value

Physical position (bp); Minor allele; Minor Allele Frequency; p-value for Hardy-Weinberg equilibrium test; Odds ratio for GI
adverse event occurrence adjusted for covariates [sex, age, BMI, integrase inhibitor (in All group), and integrase inhibitor
duration]

Nausea Occurrence. Nearly one in five of all patients (18.2%) experienced nausea.
Dolutegravir grouping exhibited slightly higher occurrence at 23.8%; while elvitegravir and
raltegravir both showed an occurrence of 13.0%. No significance (p=0.459) was found between
regimen and nausea occurrence. In the cumulative regimen group, two SNPs, rs1695 and rs1208
(Table 3), were associated with increased nausea occurrence; however, individual drug grouping
eliminated associations.
Discussion
The purpose of this study was to examine the effects of individual characteristics on adverse
event occurrence in the use of INSTI regimen. Successful completion of this project sought to
identify methods for predicting and possibly preventing negative outcomes.
Central Nervous System Adverse Events
Abnormal Dream Occurrence. When dolutegravir (50 mg) was dosed once daily to
healthy patients over five days, 8% (1/12) of patients experienced abnormal dreams (16). This
report is similar to the finding in our cohort at 9.5%. The occurrence of abnormal dreams in
elvitegravir found in our study (4.3%) was lower than those previously reported by Wohl et al..
That study reported 15% and 16% occurrence in a sample size of 348 patients following 96 and
144 weeks, respectively, when elvitegravir in combination with cobicistat, emtricitabine, and
tenofovir disoproxil fumarate was dosed (8). More patients may have had a higher frequency of
alternate genotypes than those observed in our study. In the STARTMRK and BENCHMRK
trials under all causalities, 7.5% and 0.9% experienced abnormal dreams when taking raltegravir
(17). This was much lower than our 30.4%.

The SNP, rs1143672, appears to have not been previously associated with abnormal
dreams. The ABCB1 SNPs which were associated with abnormal dream occurrence in the
raltegravir group may be related to an alteration of raltegravir concentrations in cerebrospinal
fluid (18). A higher, although nonsignificant (p=0.4419), trough concentration of raltegravir has
been reported in patients with genotypes differing from the homozygous G alleles (255±161
ng/mL vs 441±525 ng/mL) (19). In that study, rs1128503 did not influence raltegravir trough
concentration nearly as much (480±348 ng/mL vs 404±505 ng/mL; p=0.8019). The protective
effects seen in our study should be studied further to determine the interaction.
Anxiety Occurrence. In a 96 weeks study of dolutegravir plus a nucleoside reverse
transcriptase inhibitor backbone, 5% of patients presented with anxiety (20); while in a study
using dolutegravir/abacavir/lamivudine, anxiety has been reported in 2% of patients (21). The
difference seen in our study (33.3%) could be the duration of the specific regimens or the
influence of concurrent medications drugs. The percentage of patients presenting with anxiety
occurrence in our study (17.4%) was higher than those reported previously with
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate dosing 6% (94) and 10% (23).
This could be the inclusion of other medications which were not considered in this study. In the
SAILING study concerning raltegravir, 2% experienced anxiety; while 6% was discovered in the
SPRING-2 ART cohort (24). The occurrence (34.8%) was much higher in our raltegravir
grouping.
Our results indicate that, overall, anxiety occurred across the tested INSTIs. The
protective effect of rs1143672, in the SLC15A2 gene, with both abnormal dreams and anxiety
may indicate changes in drug transport are contributing to these adverse events. VKORC1 SNPs
occur frequently across variables; however, the mechanism of interaction, if valid, is unknown.
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Fatigue Occurrence. The percentage of patients experiencing fatigue while taking
dolutegravir in our study was 33.3%; while fatigue occurred in 6% and 4% of dolutegravir
patients in two previous studies by Molina et al. (20) and Cahn et al. (9), respectively. In
previous clinical studies concerning elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
fumarate, fatigue was reported in 13% and 15% of patients at 96 weeks and 144 weeks,
respectively (8). Even in the elvitegravir group, our findings of fatigue were twice (30.4%) those
in the previous study. Fatigue was reported in 7% of raltegravir patients in one study (9) and
3.9% of the patients from the STARTMRK study (17); while our values were more than five
times higher at 34.8%. One explanation of the high values in our study is that we relied on
patient reported occurrence without expansive clinical examination. Thus, the fatigue may have
alternate causes. Regardless of mechanism, we found no association between regimen and
fatigue occurrence in this population.
The SNPs associated with fatigue in the comprehensive group showed relatively low
variation as opposed to those in the raltegravir group. The results of this study seem to indicate
that a few SNPs can strongly predict fatigue occurrence with raltegravir; however, the extent of
the 95% confidence intervals are quite high. Upon confirmation in a larger population, the
variation will likely be reduced as more individuals with differing genotypes may be present.
Headache Occurrence. Seventeen percent of patients reported headaches when dosed
with dolutegravir (20) compared with 9% in another study (9); while 3% experienced headaches
when given dolutegravir/abacavir/lamivudine (21). All values were much lower than that
observed in our study (33.3%). Our 8.7% occurrence of headaches within the elvitegravir group
was much lower than the 16% (at 96 weeks) and 18% (at 144 weeks) occurrence when given the
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate regimen (8). Headache
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occurrence was reported in 9% of raltegravir patients in one study (9); while the STARTMRK
study yielded 9.3% (20). Both lower than our 17.4%. Although different, no significant
association between regimen and outcome was not found which matches our results of no
association within individual groups. The strong positive association seen with rs3213619, which
likely occurs due to alteration in drug transport, had high variability; however, upon
confirmation, this SNP may be clinically important for those wishing to avoid headaches.
Insomnia Occurrence. Molina and colleagues reported insomnia in 8% of patients
receiving dolutegravir (20); meanwhile, Walmsley et al. showed 4% occurrence when using
dolutegravir/abacavir/lamivudine (21). This is less than half of the percentage found in our study
(19.0%). Our insomnia occurrence (8.7%) was somewhat less than the 11% and 12% reported
for elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate at 96 and 144 weeks (8).
Also, the four percent of patients experienced moderate-to-severe insomnia in a previous study
concerning raltegravir (25) was much lower than our 30.4%. This may have been because we
included any occurrence of insomnia rather than moderate to severe. The high variability across
regimens would explain the absence of significant association between regimen and insomnia.
Once again VKORC1 shows association, but the interaction is unknown.
Gastrointestinal Adverse Events
Diarrhea Occurrence. Nearly one third of our patients (30.9%) reported diarrhea in the
dolutegravir group. Previously 18% of dolutegravir receiving patients reported diarrhea in the
study by Molina et al. (20) and 20% in the study by Cahn and colleagues (9); meanwhile 5% was
reported when dolutegravir/abacavir/lamivudine was given (21). We found nearly identical
occurrence (26.1%) of diarrhea as those reported for
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (25% and 26%) at 96 and 144
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weeks (8). Diarrhea was reported in 18% of raltegravir patients (9); while the STARTMRK
study reported 5.0% (20). The values are much smaller than our 30.4%. The distribution of
diarrhea in our patients was relatively uniform; thus, explaining the lack of association between
regimen and diarrhea. As catechol-o-methyltransferase, which had a significant SNP in the
comprehensive analysis, is involved in neurotransmitter metabolism the mechanism of
interaction with diarrhea not evident; however, the effect is not large (26).
Nausea Occurrence. Nausea was reported in 17% of patients receiving dolutegravir alone
(20); 8% in another study (9); and 2% in a dolutegravir/abacavir/lamivudine study (21). While in
our study 23.8% of patients reported nausea, this was similar to the first study, but much larger
than the latter two. Previously, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
showed 22% (96 weeks) and 23% (144 weeks) occurrence of nausea (8). These values are
actually a bit larger than our 13%. Nausea has been previously reported in 8% of raltegravir
patients (9) and 8.5% in the STARTMRK results (20). Once again, our value is a bit higher at
13%. As the values reported in our study are relatively close across regimens, no association was
found in Fisher’s exact testing. The associated SNPs in the comprehensive group both increase
the likelihood of nausea, but the mechanism unclear.
In addition to the limitations previously reported (15), such as small sample size, this
study depended on patient-reported adverse event occurrence which may be limited by patient
recall. These events were also left to the determination of the patient rather than clinical workup.
Also, we may have missed important SNPs as this was not a genome wide association study.
These results indicate that pharmacogenetics may play an important role in predicting the
adverse effect profile of integrase inhibitor-based regimens. As the identification of patient
outcome determinants contributes to better utilization of medication, especially in first line
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therapies such as INSTIs, these exploratory findings provide support for further examination of
precision medicine in HIV pharmacotherapy. In conclusion, the associations found in this study
strengthen the need for further assessment within the HIV positive population of factors
contributing to unfavorable patient outcomes.
Methods
Subject Recruitment
This study, as previously reported (15), was approved by the East Tennessee State
University (ETSU)/VA Medical Campus Institutional Review Board (IRB). Patients were
recruited as delineated in Figure 1. Briefly, non-pregnant adults (≥18 years) on an INSTI
regimen for HIV-1 were eligible. Following the receipt of informed consent, side effect
occurrence, including central nervous system-related (abnormal dream, anxiety, fatigue,
headache, and insomnia) and gastrointestinal-related (diarrhea and nausea), was treated as a
binary outcome (occurrence vs nonoccurrence) regardless of frequency was assessed with a
questionnaire.
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Figure 1: Subject Recruitment Schematic

Dolutegravir grouping included patients receiving 50 mg of dolutegravir in combination
with abacavir (600 mg)/lamivudine (300 mg) in a single tablet or dosed with either tenofovir
disoproxil fumarate (300 mg)/emtricitabine (200 mg) or tenofovir alafenamide (25
mg)/emtricitabine (200 mg). The elvitegravir grouped patients were administered either
elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir disoproxil fumarate (300 mg)/emtricitabine
(200 mg) or elvitegravir (150 mg)/cobicistat (150 mg)/tenofovir alafenamide (10
mg)/emtricitabine (200 mg) once daily. Raltegravir (400 mg) taken every 12 hours along with
tenofovir disoproxil fumarate (300 mg)/emtricitabine (200 mg) or tenofovir alafenamide (25
mg)/emtricitabine (200 mg) every 24 hours. Some patients were also receiving protease
inhibitors in addition to the INSTI and background regimens.
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Pharmacogenetic Analysis
An iPLEX® ADME PGx Panel v1.0 (Sequenom, San Diego, CA) was utilized to
interrogate patient SNPs. HAPLOVIEW software was used to determine Hardy-Weinberg
equilibrium (HWE), minor allele frequency (MAF), and pairwise linkage disequilibrium (LD)
statistics (r2) (27). The additive genetic association model was employed in this study with the
most frequent allele being considered as a reference.
Statistical Analysis
De-identified patient information was stored in the ETSU version of REDCap (Research
Electronic Data Capture), a secure web-based application (28). Fisher’s exact tests were used to
evaluate independence of binary adverse event outcomes among regimens and genotypes using
SPSS v25 (29). Clinical outcome associations with genotype were analyzed using multiple
logistic regression with inclusion of covariates [age, BMI, sex, regimen duration, and specific
regimen (in the comprehensive group)] via PLINK v1.07 (30). A p-value of greater than 0.05
was set as the statistical cutoff. Correction for multiple testing across Fisher’s exact tests and
logistic regression was not conducted due to the exploratory nature of this study (31).
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Study Highlights
o What is the current knowledge on the topic?
HIV antiretrovirals, which successfully suppress viral load, require life-long dosing. As such, the
occurrence of adverse events and the avoidance thereof have risen in importance. The first three
available integrase strand transfer inhibitors (INSTI) have each displayed, although relatively
rare, discontinuation-worthy adverse events.
o What question did this study address?
This study sought to analyze genetic influence, through single nucleotide polymorphism (SNP)
association, on the occurrence of such adverse events in INSTI dosing.
o What does this study add to our knowledge?
Abnormal dreams may be related to raltegravir. Additionally, several SNP associations were
discovered with various central nervous system gastrointestinal adverse events. These results
may point to additional considerations in regimen selection.
o How might this change clinical pharmacology or translational science?
These associations, if confirmed in larger studies, may help practitioners to tailor patient
regimens with greater accuracy.
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CHAPTER 4
CONCLUSIONS
The purpose of this study was to test our hypothesis that particular drug outcomes would
be influenced by the pharmacogenetics of an individual. In order to complete this project, we
evaluated INSTI drug exposure in HIV-1 patients, documented genetic polymorphisms, collected
clinical outcomes, and performed association analyses.
Drug Exposure
As outlined in Chapter 2, subjects in our study underwent Ctrough sample collection to fulfill
specific aim one. Although this method of drug exposure determination was undoubtedly less
complicated than comprehensive pharmacokinetic sampling, subjects, especially those on strict
dosing schedules, were typically reluctant to alter their routine. Thus, many potential participants
were disqualified. As Ctrough sample concentrations are characteristically low, analysis also
proved to be a difficulty. Also, high variability was seen; however, this was expected in this drug
class (Rizk et al., 2012). Additionally, differences in food intake (amount, time relative to
dosing, and composition) may have also contributed to the variability (Lampiris, 2012; Olin et
al., 2012).
Owing to the lack of intra- and inter-day data as well as the few samples that yielded
concentrations within respective standard curves (dolutegravir; n=23; elvitegravir, n=15; and
raltegravir, n=6), these data were only tested against genotype. While associations were found
only with dolutegravir, this may be a function of the others having much less variation within
genotype in the already small sample size. However, as stated earlier, the associations (Table
1.2) have not been reported prior to this study which may point to a new route of investigation.
As with the other results of this study future confirmation will give a more definitive answer.
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Genetic Analysis
The second specific aim was conducted as delineated in Chapter 2. Although alternative,
less invasive methods of DNA collection are available, the sampling used in this study was
concurrent with the whole blood collection for Ctrough determination. The completion of this
second aim was successful; however, in future studies the use of genome wide association
studies (GWASs) may be more beneficial as one-to-one SNP to outcome relationships are rare.
As opposed to individual SNP studies, several SNP studies (such as the present project), and
whole exome studies (which analyze variation within segments of the genome which code for
protein), a GWAS allows for more a comprehensive look into variations which may contribute to
several outcomes. Expression analysis would also be very helpful as the amount of protein, in
most cases, has a proportionate influence on activity (Elens et al., 2013; Okubo et al., 2013;
Wang et al., 2011). Additionally, SNPs may not give the complete picture. A SNP alone, for
example, may show full functionality regarding genotype; however, a regulating sequence may
be inoperative.
Clinical Outcomes
The third aim of this project was carried out via two routes: electronic medical record
review and questionnaire administration. Firstly, we decided to gather the results of patient
metabolic panels as these were conducted routinely. The hepatic function outcomes (ALP, ALT,
and AST) along with renal outcomes (BUN and eGFR) were gathered successfully (as outlined
in Chapter 2). A majority of these values were found to reside within the normal ranges apart
from ALT. These results likely indicate that INSTI do not generally have a large influence on
hepatic and renal parameters which is helpful as other concurrent drugs may. The elevation in
ALT may have been elicited through concurrent disease states or conditions. Overall, toleration
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was high in terms of hepatic and renal outcomes. Secondly, a questionnaire was administered, as
explained in Chapter 3. Included in the questionnaire, apart from typically demographic
information, was the question of which adverse events occurred over the previous two weeks. In
these outcomes, only abnormal dream occurrence was significantly related to regimen in which
case raltegravir showed a higher occurrence.
In addition to the hepatic and renal information for the collection time and baseline
values, consideration of more information regarding co-administered drugs may increase the
accuracy of prediction. For example, subject outcomes may be dependent based on the duration
of various background regimens. This suggestion would be more practical in a multiple
personnel setting which would allow for evaluation of various aspects of data collection. Another
improvement would be to have adverse events evaluated for relatedness to drug administration
by a physician rather than relying on subject reported events. Subjects may, for example, suffer
from migraine headaches or have an underlying psychological disorder which manifests in
anxiety or insomnia. Thus, the occurrence of an adverse event may have been reported, but due
to a preexisting condition or other factor rather than the drug of interest.
Association Analyses
Finally, association analyses were conducted, in completion of specific aim 4, between
genotype information and the variables collected from pharmacokinetic and clinical outcomes
observation. First, in terms of hepatic outcomes we saw numerous associations between
genotype and ALP, ALT, and AST (Tables 1.3, 1.4, and 1.5). However, the significant values
were found primarily in the comprehensive regimen grouping. This may have been a result of
smaller insignificant associations coalescing into significance. Regardless of reasoning, this
study was intended to open new avenues of investigation rather than concretely describe
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relationships. As some of the polymorphisms presented with relatively large effects on respective
levels, these may need to be examined further. Secondly, there were many SNP associations
found with BUN levels (Table 1.6) with primarily minor effects and the three SNPs in the
comprehensive group seemed to improve renal function as measured by eGFR (Table 1.7).
Elvitegravir grouping found SNP associations with lower eGFR. As noted earlier the presence of
cobicistat and tenofovir may have contributed to these outcomes (D. E. Murrell et al., 2015).
Thirdly, several SNP associations were found across CNS (Table 2.1) and GI (Table 2.2)
event occurrence. Abnormal dreams associations may have been associated with penetration of
raltegravir into cerebrospinal fluid (Tsuchiya et al., 2014). Our results also indicate that, overall,
anxiety occurred across the tested INSTIs. Drug transportation may help to explain the abnormal
dreams and anxiety as changes were seen when alleles changed in some SNPs. Fatigue also had
associations, but the variations were large when considering raltegravir grouping. Headache
prediction was also possible; however, the high variation lessens the strength of the result.
Insomnia, diarrhea, and nausea occurrence had associated SNPs; however, as with the other
associations the mechanisms are unclear.
As noted in Chapters 2 and 3, this study has limitations. The first being the low sample
size, in terms of regimen group size and the occurrence of different alleles, which may have
influenced study outcomes. A case-control study design may be more helpful in the future.
Another limitation is that SNPs that occur more in different people groups may have been missed
in this relatively homogenous population. A third limitation is the adverse event recording
method. Our method did not take into account alternative explanations and were not evaluated
for relatedness by a physician.
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In conclusion, we determined some patient outcomes were associated with several SNPs.
The fact that many have been previously unreported may be related to perceived clinical
significance; however, our results add to the understanding of possibly related factors.
Additionally, we found that raltegravir may need to be monitored in terms of abnormal dreams.
As INSTIs are frontline regimens, information which may inform regimen choices is important
for the prescribing physician as well as the patient.
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Table S1: Abnormal dream occurrence in associated SNPs by allele
Abnormal dream
Regimen

ALL

Raltegravir

SNP

occurrence

Allele

rs1143672 (A>G)

rs1128503 (C>T)

99

No

Yes

AA

19

6

GA

36

6

GG

21

0

CC

4

4

CT

10

3

TT

2

0

Table S2: Anxiety occurrence in associated SNPs by allele

Regimen

ALL

SNP

Anxiety
occurrence

Allele

rs1143672 (G>A)

rs9934438 (G>A)

rs9923231 (C>T)

100

No

Yes

GG

16

5

GA

34

8

AA

12

13

GG

33

9

GA

24

12

AA

5

5

CC

33

9

CT

24

12

TT

5

5

Table S3: Fatigue occurrence in associated SNPs by allele
Fatigue
Regimen

ALL

SNP

rs1128503 (C>T)

rs2070673 (T>A)

rs1902023 (G>T)

Raltegravir

occurrence

Allele

rs3892097 (G>A)

rs1065852 (C>T)

rs316019 (G>T)

101

No

Yes

CC

19

16

CT

30

13

TT

10

0

TT

41

14

TA

17

12

AA

1

3

GG

20

6

GT

27

10

TT

12

13

GG

13

3

GA

2

5

AA

0

0

CC

13

3

CT

2

4

TT

0

1

GG

14

4

GT

1

4

TT

0

0

Table S4: Headache occurrence in associated SNPs by allele
Headache
Regimen

ALL

SNP

occurrence

Allele

rs1695 (A>G)

rs2306283 (G>A)

rs3213619 (T>C)

102

No

Yes

AA

32

5

AG

32

9

GG

4

6

GG

18

4

GA

36

4

AA

14

12

TT

66

17

TC

2

3

CC

0

0

Table S5: Insomnia occurrence in associated SNPs by allele
Insomnia
Regimen

ALL

SNP

occurrence

Allele

rs9934438 (G>A)

rs9923231 (C>T)

103

No

Yes

GG

38

4

GA

26

10

AA

7

3

CC

38

4

CT

26

10

TT

7

3

Table S6: Diarrhea occurrence in associated SNPs by allele
Diarrhea
Regimen

ALL

SNP

occurrence

Allele

rs4680 (A>G)

104

No

Yes

AA

15

13

AG

29

11

GG

18

2

Table S7: Nausea occurrence in associated SNPs by allele
Nausea
Regimen

ALL

SNP

occurrence

Allele

rs1695 (A>G)

rs1208 (A>G)

105

No

Yes

AA

33

4

AG

33

8

GG

6

4

AA

31

3

AG

30

8

GG

11

5
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